Cellebrite DI Ltd. $CLBT Stake Boosted by JPMorgan Chase & Co.

JPMorgan Chase & Co. increased its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 52.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 867,373 shares of the company’s stock after acquiring an additional 300,046 shares during the period. JPMorgan Chase & Co.’s holdings in Cellebrite DI were worth $13,878,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of CLBT. Natixis Advisors LLC acquired a new position in Cellebrite DI in the 1st quarter worth about $469,000. US Bancorp DE bought a new stake in shares of Cellebrite DI in the 1st quarter valued at approximately $308,000. Swiss National Bank increased its holdings in Cellebrite DI by 27.0% in the first quarter. Swiss National Bank now owns 191,300 shares of the company’s stock worth $3,717,000 after buying an additional 40,700 shares during the last quarter. Invesco Ltd. raised its position in Cellebrite DI by 122.1% during the first quarter. Invesco Ltd. now owns 3,296,079 shares of the company’s stock valued at $64,043,000 after acquiring an additional 1,811,757 shares in the last quarter. Finally, Polen Capital Management LLC raised its position in Cellebrite DI by 47.1% during the first quarter. Polen Capital Management LLC now owns 14,849 shares of the company’s stock valued at $289,000 after acquiring an additional 4,754 shares in the last quarter. Institutional investors and hedge funds own 45.88% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have commented on CLBT shares. Needham & Company LLC boosted their target price on shares of Cellebrite DI from $22.00 to $24.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Wall Street Zen cut shares of Cellebrite DI from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Cellebrite DI in a report on Monday, December 1st. Lake Street Capital upped their price target on Cellebrite DI from $22.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Finally, JPMorgan Chase & Co. increased their price objective on Cellebrite DI from $23.00 to $24.00 and gave the company an “overweight” rating in a report on Thursday, November 13th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $24.00.

Cellebrite DI Price Performance

Cellebrite DI stock opened at $18.28 on Friday. Cellebrite DI Ltd. has a fifty-two week low of $13.10 and a fifty-two week high of $26.30. The firm has a fifty day moving average price of $17.78 and a two-hundred day moving average price of $16.53. The firm has a market cap of $4.38 billion, a price-to-earnings ratio of 58.97, a P/E/G ratio of 3.12 and a beta of 1.29.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings data on Wednesday, November 12th. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.05). Cellebrite DI had a return on equity of 20.81% and a net margin of 16.74%.The business had revenue of $126.03 million during the quarter, compared to the consensus estimate of $122.98 million. During the same quarter in the previous year, the firm posted $0.14 earnings per share. The company’s revenue for the quarter was up 17.9% on a year-over-year basis. As a group, sell-side analysts expect that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.